Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity.

@article{Mangan2015DualIO,
  title={Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity.},
  author={Paul R. Mangan and Linhui Julie Su and Victoria Jenny and Andrea L Tatum and Caryn Picarillo and Stacey Skala and Noah Ditto and Zheng Jiong Lin and Xiaoxia Yang and Pete Z Cotter and David J. Shuster and Yunling Song and Virna B. Borowski and Rochelle L Thomas and Elizabeth M Heimrich and Brigitte Devaux and Ruchira Das Gupta and Irvith Carvajal and Kim W Mcintyre and Jenny H. Xie and Qihong Zhao and Mary V Struthers and Luisa M Salter-Cid},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2015},
  volume={354 2},
  pages={152-65}
}
Therapies targeting either interleukin (IL)-23 or IL-17 have shown promise in treating T helper 17 (Th17)-driven autoimmune diseases. Although IL-23 is a critical driver of IL-17, recognition of nonredundant and independent functions of IL-23 and IL-17 has prompted the notion that dual inhibition of both IL-23 and IL-17 could offer even greater efficacy for… CONTINUE READING